studi praklinis baru
menunjukkan vaksin untuk mencegah infeksi Zika pada manusia adalah layak
ilmuwan militer
bergerak cepat untuk menguji calon vaksin
Date:
June 28, 2016
Source:
The U.S. Military HIV Research
Program (MHRP)
Summary:
Walter Reed Army Institute of Research (WRAIR) dan kolaborator di Deaconess Medical
Center Beth Israel dan Harvard Medical School telah menyelesaikan studi praklinis
menjanjikan dua kandidat vaksin Zika yang menunjukkan bahwa vaksin manusia yang
efektif akan dicapai. Temuan dari penelitian ini diterbitkan dalam jurnal Nature.
..........................
Walter Reed Army Institute of Research (WRAIR) dan kolaborator di Deaconess Medical
Center Beth Israel dan Harvard Medical School telah menyelesaikan studi praklinis
menjanjikan dua kandidat vaksin Zika yang menunjukkan bahwa vaksin manusia yang
efektif akan dicapai. Temuan dari penelitian ini diterbitkan dalam jurnal Nature.
Dalam studi praklinis, WRAIR dan Medical Center Beth Israel Deaconess menguji
dua kandidat vaksin virus Zika: vaksin DNA dikembangkan di Harvard
berdasarkan strain virus Zika yang diisolasi di Brazil, dan vaksin virus yang
tidak aktif dimurnikan yang dikembangkan di WRAIR berdasarkan pada
strain virus Zika terisolasi di Puerto Rico.
............................
SILAHKAN MENGGUNAKAN
" MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
..................................
..................................
..................................
KSE – KOMUNITAS SATWA EKSOTIK –
EXOTIC PETS
COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
........Komunitas T-REC semarang,komunitas
reptil tugumuda reptiles community semarang,komunitas reptil tugumuda
semarang,komunitas semarang,komunitas reptil semarang.............kenali dan
dalami satwa dan reptil dengan bergabung
bersama kami,hubungi 08995557626 / 764047D2.....
........Komunitas KSE ,komunitas satwa eksotik
,komunitas satwa.............kenali dan dalami satwa dan reptil dengan bergabung bersama kami,hubungi
08995557626 / 764047D2.....
.............................
................
New preclinical study indicates
vaccine to prevent Zika infection in humans is feasible
Army scientists are moving quickly
to test vaccine candidate
Date:
June 28, 2016
Source:
The U.S. Military HIV Research
Program (MHRP)
Summary:
The Walter Reed Army Institute of Research (WRAIR) and
collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical
School have completed a promising preclinical study of two Zika vaccine
candidates that suggests that an effective human vaccine will be achievable.
Findings from the study were published today in the journal Nature.
..........................
The Walter Reed Army Institute of Research
(WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and
Harvard Medical School have completed a promising preclinical study of two Zika
vaccine candidates that suggests that an effective human vaccine will be
achievable. Findings from the study were published today in the journal Nature.
In the preclinical study, WRAIR and the Beth Israel Deaconess Medical
Center tested two Zika virus vaccine candidates: a DNA vaccine developed at
Harvard based on a Zika virus strain isolated in Brazil, and a purified
inactivated virus vaccine developed at WRAIR based on a Zika virus strain
isolated in Puerto Rico.
The study showed that single shots of either vaccine candidate protected
mice against subsequent Zika challenge. Both candidates were found to be safe
and elicited an antibody response to Zika virus that correlated with
protection. Further work with the DNA vaccine demonstrated that protection was
solely due to antibodies raised by vaccination.
WRAIR is moving forward with the purified inactivated virus (PIV) vaccine,
called ZPIV, because it builds on "a type of vaccine that has been
licensed before," said Col. Stephen Thomas, an infectious disease Army
physician and a vaccinologist specializing in flaviviruses, and the WRAIR Zika
program lead. "It's the same technology WRAIR has used to successfully
develop other flavivirus vaccines." Researchers are trying to mitigate
risk by avoiding unproven technologies that could cause a licensing delay, he
noted.
Col. Nelson Michael, the WRAIR Zika program co-lead, said, "This
critical first step has informed our ongoing work in non-human primates and
gives us early confidence that development of a protective Zika virus vaccine
for humans is feasible."
WRAIR scientists are moving rapidly to develop and test the ZPIV vaccine,
and they plan to start human testing at their clinic in Silver Spring before
the end of the year. Additional human trials are planned in the United States,
supported by the National Institute of Allergy and Infectious Diseases (NIAID),
through its Vaccine and Treatment Evaluation Units.
WRAIR has been researching flaviviruses, a family of viruses that includes
Japanese encephalitis, dengue, West Nile and Zika viruses, for over half a
century. "Our laboratory in Thailand has been conducting biosurveillance
for Zika for the past three years, since we started to observe dengue-like
illnesses in Thailand and the Philippines that were not dengue and did not test
positive for other likely causes," said Thomas. "These efforts gave us
a head-start for our vaccine development efforts."
WRAIR also has in-house capabilities that have enabled them to quickly
develop a vaccine candidate. The Pilot Bioproduction Facility headed by Dr.
Kenneth H. Eckels, produced small batches of vaccine candidates that were used
for the preclinical studies and is currently manufacturing a vaccine lot for
use in initial human clinical studies.
Infectious diseases have long been a threat to U.S. Service Members, and
the military has extensive expertise and capabilities to develop
countermeasures. WRAIR is working on the vaccine in collaboration with other
U.S. government agencies, including the NIAID, part of the National Institutes
of Health, and the Biomedical Advanced Research and Development Authority, part
of the Department of Health and Human Services. It is also exploring
collaborations with pharmaceutical companies.
Support for this study was provided by the National Institutes of Health
(AI095985, AI096040, AI00663 and AI124377), the Ragon Institute of MGH, MIT and
Harvard, and the Sao Paulo Research Foundation.
Story Source:
The above post is reprinted from materials provided
by The U.S. Military HIV Research
Program (MHRP). Note: Materials may be edited
for content and length.
Journal Reference:
1. Rafael A.
Larocca, Peter Abbink, Jean Pierre S. Peron, Paolo M. de A. Zanotto, M. Justin
Iampietro, Alexander Badamchi-Zadeh, Michael Boyd, David Ng’ang’a, Marinela
Kirilova, Ramya Nityanandam, Noe B. Mercado, Zhenfeng Li, Edward T. Moseley,
Christine A. Bricault, Erica N. Borducchi, Patricia B. Giglio, David Jetton,
George Neubauer, Joseph P. Nkolola, Lori F. Maxfield, Rafael A. De La Barrera,
Richard G. Jarman, Kenneth H. Eckels, Nelson L. Michael, Stephen J. Thomas, Dan
H. Barouch. Vaccine protection against Zika virus from Brazil. Nature,
2016; DOI: 10.1038/nature18952